MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3760/cma.j.issn.0253-2727.2021.12.005

Медицинская библиотека · Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021

[Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].

Tao Y, Wang S, Wang L, Wu M, Zhao W L

СтатьяПеревод в очереди

Аннотация

Objective

This study aimed to summarize the clinical characteristics and prognosis of 108 patients with Waldenström macroglobulinemia (WM) in a single center and compare them with those of the Pivotal study with Bruton's tyrosine kinase inhibitor (BTKi) monotherapy.

Methods

The clinical characteristics, international prognostic index score (IPSS) , first-line treatment, progression-free survival (PFS) , and overall survival (OS) of 108 patients with newly diagnosed WM from March 2008 to February 2021 were retrospectively evaluated. The MYD88 mutation was tested among 52 patients.

Results

The median age of the 108 patients was 63 years (range, 38-78 years) with a male-to-female ratio of 3.5∶1. According to IPSS, we included 40% (n=43) high-risk, 33% (n=36) intermediate-risk, and 27% (n=29) low-risk patients. In this study, no significant difference was observed in age, gender, IPSS risk, serum immunoglobulin M (IgM) , and platelet counts compared to the baseline characteristics of 63 patients in the pivotal study. However, hemoglobin (86 g/L vs 105 g/L) , serum β(2)-MG (3.1 mg/L vs 3.9 mg/L) , bone marrow involvement (13% vs 60%) , and the proportion of adenopathy (41% vs 59%) were significantly lower than those in the Pivotal group. The proportion of patients with splenomegaly (27% vs 11%) was significantly higher than that of the Pivotal group. All the differences were statistically different (all P values <0.05) . The overall positive rate of MYD88 mutation was 77%. With a median follow-up of 36 (1-121) months, the median OS was 95 months, and the median PFS was 35 months. The 2-year OS rate (83% vs 96%) and 5-year OS rate (67% vs 87%) of patients with WM in our center were lower than those in the Pivotal group. The proportion of novel treatments based on BTKi, CD20 monoclonal antibody, and proteasome inhibitors in our center from 2008 to 2021 has gradually increased from 50% to 93%. The long-term OS of patients diagnosed in 2015-2021 was improved compared with that in 2008-2014 (P=0.048) .

Conclusions

Novel drugs, including BTKi, continue to benefit patients with WM and improve their survival. It is worthwhile to further explore the positivity of MYD88 and CXCR4 mutations in the Chinese population and their sensitivity to BTKi.

Для цитирования: Tao Y, Wang S, Wang L, Wu M, Zhao W L. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2021. DOI: 10.3760/cma.j.issn.0253-2727.2021.12.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.